Aviado · Research
Longevity Daily
Friday, October 9, 2026
Listen
Today's Brief
Today's issue centers on a genuine milestone: the first human data from a cellular reprogramming gene therapy is in, making longevity's most audacious bet feel real. A pooled analysis of 13 trials and 90,000 patients makes the strongest case yet that SGLT inhibitors outperform rapamycin and metformin as geroprotectors. Meanwhile, a genetic study of 187,000 older adults links ADHD to a fourfold increase in dementia risk, and New Scientist digs into the glymphatic system as a next-generation Alzheimer's target. Aviado's analysis of olive leaf extract rounds out the issue with a clear protocol — and a reminder that this supplement only works for those with elevated baseline numbers.
10 stories5 peer-reviewed2 trials1 Aviado original
Cognitive Health & Neuroprotection
Adults With ADHD Face More Than 4x the Long-Term Dementia Risk, Backed by Genetic Evidence
A genetic analysis of 187,000 older adults finds that adults with ADHD carry more than four times the long-term risk of developing dementia — and Mendelian randomization data suggests this relationship is likely causal, not just correlation. For people managing adult ADHD, this makes proactive brain health strategies a higher priority than most clinicians currently communicate: quality sleep, cardiovascular fitness, and early cognitive baseline testing all become more urgent. The study doesn't yet explain the full mechanism, but neuroinflammation and dopaminergic dysregulation are leading suspects.
Read more →The Brain's Hidden Cleaning System Could Be a Key Target for Alzheimer's Prevention
The glymphatic system — a cerebrospinal fluid network that clears beta-amyloid and tau from the brain primarily during deep sleep — is emerging as one of the most promising targets for Alzheimer's prevention. Research in both mice and humans now shows that glymphatic dysfunction precedes amyloid plaque formation, suggesting it's a cause of Alzheimer's rather than just a consequence. The most actionable implication: anything that disrupts deep sleep — alcohol, poor sleep hygiene, apnea — may be accelerating brain waste accumulation over decades.
Read more →Supplements & Compounds
Fish Oil Cuts Major Cardiovascular Events by 43% in High-Risk Patients
Researchers report a 43% lower rate of serious cardiovascular events — heart attack, stroke, and cardiac death — in high-risk patients supplementing with fish oil versus placebo. The effect size is particularly striking because this group faces an already-elevated baseline risk, making the absolute benefit even more significant. If you fall into a high-risk cardiovascular category, this is one of the cleaner supplement stories of the year.
Read more →Olive Leaf Extract Works for Blood Pressure — But Only if Your Numbers Are Already High
Olive leaf extract can reduce systolic blood pressure by 6–15 points and triglycerides by 9–22 mg/dL — but only if your baseline numbers are elevated (systolic 130+ mmHg, triglycerides 150+ mg/dL). In people with normal readings, the effect is essentially zero, making this one of the clearest examples of a supplement that works conditionally, not universally. Aviado's protocol: 500 mg of standardized extract twice daily with meals for 12 weeks, with weekly home monitoring to track your individual response.
Read the full Aviado analysis →Research & Papers
Science Journal: Why Larger Dogs Age Faster — And What Their DNA Reveals About Longevity
A study of 1,640 DNA methylation profiles from 894 dogs, published in Science, confirms that larger dogs age faster at the molecular level — with transposable elements (mobile DNA sequences) emerging as mediators of the size-lifespan relationship. Both larger and male dogs show accelerated epigenetic aging, with sex-dependent changes concentrated on the X chromosome and size-associated changes pronounced at transposable elements. For longevity researchers, dogs represent one of the best natural experiments in mammalian aging: same species, wildly different lifespans, and now a molecular roadmap for why.
Read more →Cardiologists Rank SGLT Inhibitors Above Rapamycin and Metformin as the Best Available Geroprotector
Four cardiologists at Saint Luke's Mid America Heart Institute pooled 13 placebo-controlled trials covering 90,413 patients and found SGLT inhibitors (dapagliflozin, empagliflozin) deliver a 12% relative reduction in all-cause mortality and 10% reduction in first hospitalization. Their argument is straightforward: while rapamycin has exciting mechanistic evidence and metformin has decades of use, only SGLT inhibitors have this scale and quality of human outcome data. For longevity-focused readers exploring pharmacological geroprotection, this meta-analysis is worth bringing to your physician.
Read more →Surprising Finding: Being Overweight at Dementia Diagnosis May Actually Extend Survival
A study of more than 4,500 adults finds that people who were overweight or obese at the time of their dementia diagnosis had significantly lower mortality risk compared to those with normal BMI — a counterintuitive pattern researchers attribute to metabolic reserves providing protection during physiological stress. This is a caveat-heavy finding: it applies after diagnosis and should not be interpreted as a reason to gain weight before dementia. It does, however, add to the evidence for the "obesity paradox" in late-life disease and may matter for how clinicians manage weight in older patients who already have dementia.
Read more →Lifestyle & Nutrition
A $399 Biological Age Test Promised to Reveal Their Organ Ages — The NYT Asks Hard Questions
The New York Times followed two sisters who each paid $399 for TruAge, an epigenetic test claiming to report the biological age of the brain, heart, lungs, and body based on DNA methylation patterns. The piece is a useful consumer reality check: the underlying clock science is legitimate, but translating a methylation pattern into a specific "organ age" remains scientifically contested, and no study has shown that acting on these scores improves actual health outcomes. Before you spend $400 on a biological age test, this is required reading.
Read more →Industry & Policy
First Human Data From a Cellular Reprogramming Gene Therapy Is In — and the Results Are Turning Heads
Life Biosciences is presenting the first human Phase 1 data from ER-100, a gene therapy that activates three Yamanaka reprogramming factors — OCT4, SOX2, and KLF4 — inside the aging eye to restore retinal ganglion cell function, marking the first time cellular reprogramming has been tested in actual patients. Business Insider's deep-dive situates this within a rapidly accelerating field: Sam Altman's Retro Biosciences is researching reprogramming, multiple pharma giants showcased longevity pipelines at the 2026 ARDD Conference in Boston, and liver-cell reprogramming trials are planned for 2027. Phase 1 data is primarily about safety, not efficacy — important context before the headlines get ahead of the science. But the fact that reprogramming is in humans at all is the milestone the field has been waiting for.
Read more →Nonprofit Hospitals Are Quietly Cashing In on the Longevity Boom
Major nonprofit health systems are launching longevity clinics, according to STAT News, moving aggressively into the optimization-focused health market once dominated by boutique concierge practices. The shift signals that longevity medicine is going mainstream — though it also raises legitimate questions about whether institutional delivery can maintain the personalized, proactive approach that defines the field's value proposition. For consumers, more access points are welcome; for the industry, the entry of large nonprofits could reshape competitive dynamics and pricing.
Read more →